留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

原发性眼内淋巴瘤的诊疗进展

梁晓杰 王亮

梁晓杰, 王亮. 原发性眼内淋巴瘤的诊疗进展[J]. 协和医学杂志, 2021, 12(4): 537-543. doi: 10.12290/xhyxzz.20190100
引用本文: 梁晓杰, 王亮. 原发性眼内淋巴瘤的诊疗进展[J]. 协和医学杂志, 2021, 12(4): 537-543. doi: 10.12290/xhyxzz.20190100
LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. doi: 10.12290/xhyxzz.20190100
Citation: LIANG Xiaojie, WANG Liang. Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma[J]. Medical Journal of Peking Union Medical College Hospital, 2021, 12(4): 537-543. doi: 10.12290/xhyxzz.20190100

原发性眼内淋巴瘤的诊疗进展

doi: 10.12290/xhyxzz.20190100
基金项目: 

国家自然科学基金 81873450

详细信息
    通讯作者:

    王亮 电话:010-58268442,E-mail:wangliangtrhos@126.com

  • 中图分类号: R557+.4;S857.6

Current Status of the Diagnosis and Treatment of Primary Intraocular Lymphoma

Funds: 

National Natural Science Foundation of China 81873450

More Information
  • 摘要: 原发性眼内淋巴瘤(primary intraocular lymphoma,PIOL)是一种罕见的淋巴细胞恶性肿瘤。目前,PIOL的诊断仍面临一定挑战,组织细胞病理活检是诊断的金标准,基因检测、细胞因子检测、流式细胞分析技术等多种检测方法联合应用可提高其诊断准确率。PIOL的标准化治疗方案尚未达成共识,局部放疗、玻璃体腔内化疗和大剂量全身化疗是控制疾病的有效手段。鉴于PIOL预后差、易复发的特点,早期诊断和治疗非常重要。
    作者贡献:梁晓杰负责文献检索、文章撰写及修订;王亮负责文章修订。
    利益冲突:
  • [1] Tang LJ, Gu CL, Zhang P. Intraocular lymphoma[J]. Int J Ophthalmol, 2017, 10: 1301-1307.
    [2] Chaput F, Amer R, Baglivo E, et al. Intraocular T-cell Lymphoma: Clinical Presentation, Diagnosis, Treatment, and Outcome[J]. Ocul Immunol Inflamm, 2017, 25: 639-648. http://europepmc.org/abstract/MED/27002464
    [3] Bohn JP, Willenbacher W, Haas G, et al. Pomalidomide in primary intraocular lymphoma[J]. Leuk Lymphoma, 2019, 60: 1584-1586. doi:  10.1080/10428194.2018.1538508
    [4] Cho BJ, Yu HG. Risk factors for intraocular involvement in patients with primary central nervous system lymphoma[J]. J Neurooncol, 2014, 120: 523-529. doi:  10.1007/s11060-014-1581-4
    [5] Mochizuki M, Singh AD. Epidemiology and clinical features of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17: 69-72. doi:  10.1080/09273940902957305
    [6] Goto H, Mochizuki M, Yamaki K, et al. Epidemiological survey of intraocular inflammation in Japan[J]. Jpn J Ophthalmol, 2007, 51: 41-44. doi:  10.1007/s10384-006-0383-4
    [7] Sagoo MS, Mehta H, Swampillai AJ, et al. Primary intraocular lymphoma[J]. Surv Ophthalmol, 2014, 59: 503-516. doi:  10.1016/j.survophthal.2013.12.001
    [8] Chan CC, Rubenstein JL, Coupland SE, et al. Primary vitreoretinal lymphoma: a report from an International Primary Central Nervous System Lymphoma Collaborative Group symposium[J]. Oncologist, 2011, 16: 1589-1599. doi:  10.1634/theoncologist.2011-0210
    [9] Chan CC. Primary intraocular lymphoma: clinical features, diagnosis, and treatment[J]. Clin Lymphoma, 2003, 4: 30-31. doi:  10.1016/S1526-9655(11)70005-7
    [10] Kimura K, Usui Y, Goto H. Clinical features and diagno-stic significance of the intraocular fluid of 217 patients with intraocular lymphoma[J]. Jpn J Ophthalmol, 2012, 56: 383-389. doi:  10.1007/s10384-012-0150-7
    [11] Mashayekhi A, Shukla SY, Shields JA, et al. Choroidal lymphoma: clinical features and association with systemic lymphoma[J]. Ophthalmology, 2014, 121: 342-351. doi:  10.1016/j.ophtha.2013.06.046
    [12] Kiratli H, Ağin A, Büyükeren B, et al. Primary Diffuse Large B-Cell Lymphoma of the Ciliary Body[J]. Ocul Immunol Inflamm, 2019, 27: 407-409. doi:  10.1080/09273948.2017.1415362
    [13] Chan CC, Sen HN. Current concepts in diagnosing and managing primary vitreoretinal (intraocular) lymphoma[J]. Discov Med, 2013, 15: 93-100.
    [14] Casady M, Faia L, Nazemzadeh M, et al. Fundus autofluorescence patterns in primary intraocular lymphoma[J]. Retina, 2014, 34: 366-372. doi:  10.1097/IAE.0b013e31829977fa
    [15] Majumder PD, Raghothaman N, Kharel R, et al. Retinal necrosis as the initial presentation of primary intraocular lymphoma[J]. Nepal J Ophthalmol, 2017, 9: 83-86. doi:  10.3126/nepjoph.v9i1.17541
    [16] Grimm SA, McCannel CA, Omuro AM, et al. Primary CNS lymphoma with intraocular involvement: International PCNSL Collaborative Group Report[J]. Neurology, 2008, 71: 1355-1360. doi:  10.1212/01.wnl.0000327672.04729.8c
    [17] Hwang CS, Yeh S, Bergstrom CS. Diagnostic vitrectomy for primary intraocular lymphoma: when, why, how?[J]. Int Ophthalmol Clin, 2014, 54: 155-171. doi:  10.1097/IIO.0000000000000022
    [18] Fend F, Ferreri AJ, Coupland SE. How we diagnose and treat vitreoretinal lymphoma[J]. Br J Haematol, 2016, 173: 680-692. doi:  10.1111/bjh.14025
    [19] Konstantinidis L, Angi M, Coupland SE, et al. Primary B-cell lymphoma of the ciliary body with 360° ('ring'-like) growth pattern[J]. Eye (Lond), 2014, 28: 355-356. doi:  10.1038/eye.2013.282
    [20] Hoang-Xuan K, Bessell E, Bromberg J, et al. Diagnosis and treatment of primary CNS lymphoma in immunocompetent patients: guidelines from the European Association for Neuro-Oncology[J]. Lancet Oncol, 2015, 16: e322-e332. doi:  10.1016/S1470-2045(15)00076-5
    [21] Keino H, Okada AA, Watanabe T, et al. Spectral-domain Optical Coherence Tomography Patterns in Intraocular Lymphoma[J]. Ocul Immunol Inflamm, 2016, 24: 268-273. http://europepmc.org/abstract/med/25760916
    [22] Fardeau C, Lee CP, Merle-Béral H, et al. Retinal fluorescein, indocyanine green angiography, and optic coher-ence tomography in non-Hodgkin primary intraocular lymphoma[J]. Am J Ophthalmol, 2009, 147: 886-894. doi:  10.1016/j.ajo.2008.12.025
    [23] Davis JL, Viciana AL, Ruiz P. Diagnosis of intraocular lymphoma by flow cytometry[J]. Am J Ophthalmol, 1997, 124: 362-372. doi:  10.1016/S0002-9394(14)70828-1
    [24] Missotten T, Tielemans D, Bromberg JE, et al. Multicolor flowcytometric immunophenotyping is a valuable tool for detection of intraocular lymphoma[J]. Ophthalmology, 2013, 120: 991-996. doi:  10.1016/j.ophtha.2012.11.007
    [25] Hiemcke-Jiwa LS, Ten Dam-van Loon NH, Leguit RJ, et al. Potential Diagnosis of Vitreoretinal Lymphoma by Detection of MYD88 Mutation in Aqueous Humor With Ultrasensitive Droplet Digital Polymerase Chain Reaction[J]. JAMA Ophthalmol, 2018, 136: 1098-1104. doi:  10.1001/jamaophthalmol.2018.2887
    [26] Tuo J, Shen D, Yang HH, et al. Distinct microRNA-155 expression in the vitreous of patients with primary vitreore-tinal lymphoma and uveitis[J]. Am J Ophthalmol, 2014, 157: 728-734. doi:  10.1016/j.ajo.2013.12.014
    [27] Ohta K, Sano K, Imai H, et al. Cytokine and molecular analyses of intraocular lymphoma[J]. Ocul Immunol Inflamm, 2009, 17: 142-147. doi:  10.1080/09273940802702553
    [28] Cassoux N, Giron A, Bodaghi B, et al. IL-10 measurement in aqueous humor for screening patients with suspicion of primary intraocular lymphoma[J]. Invest Ophthalmol Vis Sci, 2007, 48: 3253-3259. doi:  10.1167/iovs.06-0031
    [29] Wolf LA, Reed GF, Buggage RR, et al. Vitreous cytokine levels[J]. Ophthalmology, 2003, 110: 1671-1672. doi:  10.1016/S0161-6420(03)00811-X
    [30] Kim MM, Dabaja BS, Medeiros J, et al. Survival Outcomes of Primary Intraocular Lymphoma: A Single-institution Experience[J]. Am J Clin Oncol, 2016, 39: 109-113. doi:  10.1097/COC.0000000000000028
    [31] Levasseur SD, Wittenberg LA, White VA. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes[J]. JAMA Ophthalmol, 2013, 131: 50-55. doi:  10.1001/jamaophthalmol.2013.569
    [32] Milgrom SA, Cheah CY, Pinnix CC, et al. Acute and late toxicity of bilateral orbital irradiation in the management of primary intraocular lymphoma[J]. Leuk Lymphoma, 2016, 57: 2612-2618. doi:  10.3109/10428194.2016.1166490
    [33] Teckie S, Yahalom J. Primary intraocular lymphoma: treatment outcomes with ocular radiation therapy alone[J]. Leuk Lymphoma, 2014, 55: 795-801. doi:  10.3109/10428194.2013.819576
    [34] Ma WL, Hou HA, Hsu YJ, et al. Clinical outcomes of primary intraocular lymphoma patients treated with front-line systemic high-dose methotrexate and intravitreal methotrexate injection[J]. Ann Hematol, 2016, 95: 593-601. doi:  10.1007/s00277-015-2582-x
    [35] Tempescul A, Pradier O, Marianowski-Cochard C, et al. Combined therapy associating systemic platinum-based chemotherapy and local radiotherapy into the treatment of primary intraocular lymphoma[J]. Ann Hematol, 2011, 90: 1117-1118. doi:  10.1007/s00277-010-1139-2
    [36] Frenkel S, Hendler K, Siegal T, et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience[J]. Br J Ophthalmol, 2008, 92: 383-388. doi:  10.1136/bjo.2007.127928
    [37] Kitzmann AS, Pulido JS, Mohney BG, et al. Intraocular use of rituximab[J]. Eye (Lond), 2007, 21: 1524-1527. doi:  10.1038/sj.eye.6702804
    [38] Kim H, Csaky KG, Chan CC, et al. The pharmacok-inetics of rituximab following an intravitreal injection[J]. Exp Eye Res, 2006, 82: 760-766. doi:  10.1016/j.exer.2005.09.018
    [39] Ghesquieres H, Chevrier M, Laadhari M, et al. Lenalido-mide in combination with intravenous rituximab (REVRI) in relapsed/refractory primary CNS lymphoma or primary intraocular lymphoma: a multicenter prospective'proof of concept'phase Ⅱ study of the French Oculo-Cerebral lymphoma (LOC) Network and the Lymphoma Study Association (LYSA)[J]. Ann Oncol, 2019, 30: 621-628. doi:  10.1093/annonc/mdz032
    [40] Lionakis MS, Dunleavy K, Roschewski M, et al. Inhibi-tion of B Cell Receptor Signaling by Ibrutinib in Primary CNS Lymphoma[J]. Cancer Cell, 2017, 31: 833-843. doi:  10.1016/j.ccell.2017.04.012
    [41] Wang L, Guan W, Peng X. Targeting Bruton Tyrosine Kinase With Zanubrutinib for Treatment of Vitreoretinal Lymphoma: Report of 3 Cases[J]. Front Oncol, 2021, 11: 676792. doi:  10.3389/fonc.2021.676792
    [42] Goodman A, Patel SP, Kurzrock R. PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas[J]. Nat Rev Clin Oncol, 2017, 14: 203-220. doi:  10.1038/nrclinonc.2016.168
    [43] Nayak L, Iwamoto FM, LaCasce A, et al. PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma[J]. Blood, 2017, 129: 3071-3073. doi:  10.1182/blood-2017-01-764209
    [44] Schorb E, Finke J, Ihorst G, et al. Age-adjusted high-dose chemotherapy and autologous stem cell transplant in elderly and fit primary CNS lymphoma patients[J]. BMC Cancer, 2019, 19: 287. doi:  10.1186/s12885-019-5473-z
    [45] Ferreri AJ, Blay JY, Reni M, et al. Prognostic scoring system for primary CNS lymphomas: the International Extranodal Lymphoma Study Group experience[J]. J Clin Oncol, 2003, 21: 266-272. doi:  10.1200/JCO.2003.09.139
  • 加载中
计量
  • 文章访问数:  962
  • HTML全文浏览量:  339
  • PDF下载量:  192
  • 被引次数: 0
出版历程
  • 收稿日期:  2019-06-04
  • 录用日期:  2019-10-12
  • 网络出版日期:  2019-10-12
  • 刊出日期:  2021-07-30

目录

    /

    返回文章
    返回

    【温馨提醒】近日,《协和医学杂志》编辑部接到作者反映,有多名不法人员冒充期刊编辑发送见刊通知,鼓动作者添加微信,从而骗取版面费的行为。特提醒您,本刊与作者联系的方式均为邮件通知或电话,稿件进度通知邮箱为:mjpumch@126.com,编辑部电话为:010-69154261,请提高警惕,谨防上当受骗!如有任何疑问,请致电编辑部核实。谢谢!